BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30875730)

  • 1. Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.
    Lim M; Puttick S; Houston ZH; Thurecht KJ; Kalita-de Croft P; Mahler S; Rose SE; Jeffree RL; Mazzieri R; Dolcetti R; Lakhani SR; Saunus JM
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
    Owyong M; Hosseini-Nassab N; Efe G; Honkala A; van den Bijgaart RJE; Plaks V; Smith BR
    Drug Resist Updat; 2017 Nov; 33-35():23-35. PubMed ID: 29145972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
    Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
    Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma in the brain: biology and therapeutic options.
    Gibney GT; Forsyth PA; Sondak VK
    Melanoma Res; 2012 Jun; 22(3):177-83. PubMed ID: 22495668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
    Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
    Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Melanoma brain metastases : Treatment options].
    Rauschenberg R; Tabatabai G; Troost EG; Garzarolli M; Beissert S; Meier F
    Hautarzt; 2016 Jul; 67(7):536-43. PubMed ID: 27206449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Perspectives in Glioblastoma: Nanoparticles-based Approaches.
    Luciano R; Battafarano G; Saracino R; Rossi M; Perrotta A; Manco M; Muraca M; Del Fattore A
    Curr Cancer Drug Targets; 2017; 17(3):203-220. PubMed ID: 27528362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent nano delivery systems for selective imaging and treatment of brain tumors.
    Ljubimova JY; Sun T; Mashouf L; Ljubimov AV; Israel LL; Ljubimov VA; Falahatian V; Holler E
    Adv Drug Deliv Rev; 2017 Apr; 113():177-200. PubMed ID: 28606739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging treatments for brain metastases.
    Lin J; Jandial R; Nesbit A; Badie B; Chen M
    Oncology (Williston Park); 2015 Apr; 29(4):250-7. PubMed ID: 25952487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
    Zhang B; Shi W; Jiang T; Wang L; Mei H; Lu H; Hu Y; Pang Z
    Oncotarget; 2016 Sep; 7(38):62607-62618. PubMed ID: 27566585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current chemotherapeutic regimens for brain metastases treatment.
    Nam JY; O'Brien BJ
    Clin Exp Metastasis; 2017 Oct; 34(6-7):391-399. PubMed ID: 28918542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.